- Home
- SBGI vs PCRX Comparison
SBGI vs PCRX Comparison
Compare SBGI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- PCRX
- Stock Information
- Founded
- SBGI 1986
- PCRX 2006
- Country
- SBGI United States
- PCRX United States
- Employees
- SBGI N/A
- PCRX N/A
- Industry
- SBGI Broadcasting
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- PCRX Health Care
- Exchange
- SBGI Nasdaq
- PCRX Nasdaq
- Market Cap
- SBGI 997.6M
- PCRX 1.1B
- IPO Year
- SBGI 1995
- PCRX 2011
- Fundamental
- Price
- SBGI $14.39
- PCRX $22.69
- Analyst Decision
- SBGI Buy
- PCRX Buy
- Analyst Count
- SBGI 5
- PCRX 9
- Target Price
- SBGI $19.30
- PCRX $26.22
- AVG Volume (30 Days)
- SBGI 333.0K
- PCRX 823.4K
- Earning Date
- SBGI 05-07-2025
- PCRX 05-06-2025
- Dividend Yield
- SBGI 6.94%
- PCRX N/A
- EPS Growth
- SBGI N/A
- PCRX N/A
- EPS
- SBGI 4.69
- PCRX N/A
- Revenue
- SBGI $3,548,000,000.00
- PCRX $700,966,000.00
- Revenue This Year
- SBGI N/A
- PCRX $9.77
- Revenue Next Year
- SBGI $2.53
- PCRX $9.83
- P/E Ratio
- SBGI $3.07
- PCRX N/A
- Revenue Growth
- SBGI 13.21
- PCRX 3.85
- 52 Week Low
- SBGI $11.13
- PCRX $11.16
- 52 Week High
- SBGI $18.45
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- SBGI 48.38
- PCRX 40.27
- Support Level
- SBGI $13.63
- PCRX $21.83
- Resistance Level
- SBGI $15.05
- PCRX $24.23
- Average True Range (ATR)
- SBGI 0.79
- PCRX 1.22
- MACD
- SBGI 0.04
- PCRX -0.36
- Stochastic Oscillator
- SBGI 64.54
- PCRX 17.70
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.